LYON, France--(BUSINESS WIRE)--Flamel Technologies S.A. (NASDAQ: FLML) today announced that it has entered into two new feasibility agreements to apply its Medusa® platform with two additional companies. One program is designed to deliver a controlled release of a marketed hormone; the other is a Medusa formulation of a therapeutic peptide. The Company is currently working on nineteen feasibility programs with fifteen partner companies. These products are in addition to the new product collaborations announced earlier this week.
